Anti-CLDN18.2 Reference Antibody (zolbetuximab)
产品介绍
Zolbetuximab (IMAB362) 是一种靶向 Claudin-18.2 的单克隆抗体，通过免疫效应机制介导对 Claudin-18.2 阳性细胞的特异性杀伤。
产品性质
产品特色
应用案例
Purity:SDS-PAGE
Anti-CLDN18.2 Reference Antibody (zolbetuximab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
Purity:SEC-HPLC
The purity of Anti-CLDN18.2 Reference Antibody (zolbetuximab) is 96.05%, determined by SEC-HPLC.
Bioactivity:ELISA
Immobilized human CLDN18.2 VLP at 2 ug/mL can bind Anti-CLDN18.2 Reference Antibody (zolbetuximab), EC50=0.07951 ug/mL.
Research in vivo
Zolbetuximab inhibited the tumor growth of CLDN18.2-MC38 (Mouse colorectal cancer cells) on C57BL/6N mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 42.3% at 10 mpk at D25.
存储条件
-25~-15℃保存，有效期1年。
COA
相关产品
联系我们
